Royalty Pharma buys cliramitug royalty stake
Royalty Pharma will pay Neurimmune $125 million upfront for a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune will receive another $125 million in Q1 2027 and up to $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase III DepleTTR-CM, with results expected in 2028.
How this was made
The 30-second read
Why it matters
The transaction increases Royalty Pharma’s development-stage pipeline exposure to a late-stage program, with cash payments split between an upfront amount, a 2027 payment, and milestone-based contingent consideration.
Market read
Traders can reassess ROY’s near-to-medium term risk profile based on a new royalty acquisition tied to a Phase III readout and regulatory path.
What to watch
The article cites AstraZeneca’s peak sales target but does not quantify probability-weighted outcomes or how royalty rates compare to other ATTR-CM deals, which could affect perceived value.
Background
Royalty Pharma is acquiring a royalty interest in cliramitug, a TTR-fibril-depleting antibody in Phase III for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Market effects
Highlights continued capital flow into late-stage royalty financing for cardiology and ATTR-CM therapeutics.
None explicitly stated.
Worldwide net sales royalty structure ties returns to global ATTR-CM commercialization.
Counterpoint
Royalty economics are attractive, but the majority of value is contingent on cliramitug achieving predetermined clinical and regulatory milestones, leaving substantial binary risk.
Key entities
- companyRoyalty Pharma
Buyer of the cliramitug royalty stake, paying upfront and additional cash tied to timing and milestones.
- companyNeurimmune
Seller of the royalty stake, receiving upfront and later payments while retaining most royalty and milestone interests.
- drugcliramitug
Phase III TTR-fibril-depleting antibody targeting existing amyloid deposits in ATTR-CM; results expected in 2028.
- companyAstraZeneca
Previously highlighted commercial potential for cliramitug at an investor day, citing a peak sales target.
